ITMI20041033A1 - Composti farmaceutici - Google Patents

Composti farmaceutici

Info

Publication number
ITMI20041033A1
ITMI20041033A1 IT001033A ITMI20041033A ITMI20041033A1 IT MI20041033 A1 ITMI20041033 A1 IT MI20041033A1 IT 001033 A IT001033 A IT 001033A IT MI20041033 A ITMI20041033 A IT MI20041033A IT MI20041033 A1 ITMI20041033 A1 IT MI20041033A1
Authority
IT
Italy
Prior art keywords
formula
following
group selected
group
pharmaceutical compounds
Prior art date
Application number
IT001033A
Other languages
English (en)
Inventor
Paolo Lazzari
Gabriele Marineddu
Gerard Aime Pinna
Stefania Ruiu
Original Assignee
Neuroscienze S C A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroscienze S C A R L filed Critical Neuroscienze S C A R L
Priority to IT001033A priority Critical patent/ITMI20041033A1/it
Publication of ITMI20041033A1 publication Critical patent/ITMI20041033A1/it
Priority to CA2507710A priority patent/CA2507710C/en
Priority to EP05010832A priority patent/EP1602658B1/en
Priority to ES05010832T priority patent/ES2378379T3/es
Priority to AT05010832T priority patent/ATE536357T1/de
Priority to US11/134,502 priority patent/US7485730B2/en
Priority to JP2005150888A priority patent/JP5073177B2/ja
Priority to US12/330,434 priority patent/US8106218B2/en
Priority to US13/327,974 priority patent/US20120088751A1/en
Priority to JP2012113543A priority patent/JP2012180366A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT001033A 2004-05-24 2004-05-24 Composti farmaceutici ITMI20041033A1 (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IT001033A ITMI20041033A1 (it) 2004-05-24 2004-05-24 Composti farmaceutici
CA2507710A CA2507710C (en) 2004-05-24 2005-05-17 Tricyclic pyrazole derivatives and their use as cb1 or cb2 modulators
EP05010832A EP1602658B1 (en) 2004-05-24 2005-05-19 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists
ES05010832T ES2378379T3 (es) 2004-05-24 2005-05-19 Derivados tricíclicos de pirazol, como antagonistas de los receptores cannabinoides
AT05010832T ATE536357T1 (de) 2004-05-24 2005-05-19 Tricyclische pyrazolderivate als cannabinoidrezeptorantagonisten
US11/134,502 US7485730B2 (en) 2004-05-24 2005-05-23 Pharmaceutical compounds
JP2005150888A JP5073177B2 (ja) 2004-05-24 2005-05-24 医薬化合物
US12/330,434 US8106218B2 (en) 2004-05-24 2008-12-08 Pharmaceutical compounds
US13/327,974 US20120088751A1 (en) 2004-05-24 2011-12-16 Pharmaceutical compounds
JP2012113543A JP2012180366A (ja) 2004-05-24 2012-05-17 医薬化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001033A ITMI20041033A1 (it) 2004-05-24 2004-05-24 Composti farmaceutici

Publications (1)

Publication Number Publication Date
ITMI20041033A1 true ITMI20041033A1 (it) 2004-08-24

Family

ID=34936679

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001033A ITMI20041033A1 (it) 2004-05-24 2004-05-24 Composti farmaceutici

Country Status (7)

Country Link
US (3) US7485730B2 (it)
EP (1) EP1602658B1 (it)
JP (2) JP5073177B2 (it)
AT (1) ATE536357T1 (it)
CA (1) CA2507710C (it)
ES (1) ES2378379T3 (it)
IT (1) ITMI20041033A1 (it)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
NZ552670A (en) * 2004-07-12 2010-02-26 Cadila Healthcare Ltd Tricyclic pyrazole derivatives as cannabinoid receptor modulators
EP1757587A1 (en) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US7897589B2 (en) * 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US8194132B2 (en) * 2006-01-20 2012-06-05 Old World Industries, Llc System for monitoring an area adjacent a vehicle
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
IT1393930B1 (it) * 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1393931B1 (it) 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composizione di spore di batteri non patogeni
IT1395724B1 (it) * 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
SG178907A1 (en) * 2009-08-28 2012-04-27 Arena Pharm Inc Cannabinoid receptor modulators
CN101863903B (zh) * 2010-06-08 2014-03-12 沈阳药科大学 1,4-二氢噻吩并[3’,2’:5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物及其应用
KR101586714B1 (ko) * 2011-09-30 2016-01-19 내셔날 헬스 리서치 인스티튜트 피라졸 화합물
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
EP2789619A1 (en) 2013-04-12 2014-10-15 Kemotech S.r.l. Pharmaceutical compounds wiht angiogenesis inbhibitory activity
US10308712B2 (en) 2014-03-27 2019-06-04 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
WO2017046371A1 (en) * 2015-09-18 2017-03-23 Sennheiser Electronic Gmbh & Co. Kg Method of stereophonic recording and binaural earphone unit
AU2016330471B2 (en) 2015-09-30 2022-09-29 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
WO2023089612A1 (en) * 2021-11-19 2023-05-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peripheral cb1 receptor antagonists for treatment of lower urinary tract symptoms (luts)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
ES2126773T3 (es) * 1993-09-15 1999-04-01 Merck Sharp & Dohme Derivados triciclicos heteroaromaticos condensados como ligandos de subtipos de receptores de dopamina.
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
EP0971588B1 (en) * 1997-01-21 2004-03-17 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
DK1268435T3 (da) 2000-03-23 2007-03-12 Solvay Pharm Bv 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk aktivitet
US20040127492A1 (en) * 2002-02-19 2004-07-01 Pharmacia Corporation Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
BR0307796A (pt) * 2002-02-19 2004-12-21 Pharmacia Corp Derivados tricìclicos de pirazol para o tratamento de inflamação
CA2526578C (en) * 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Also Published As

Publication number Publication date
JP2012180366A (ja) 2012-09-20
ES2378379T3 (es) 2012-04-11
US7485730B2 (en) 2009-02-03
EP1602658A1 (en) 2005-12-07
ATE536357T1 (de) 2011-12-15
US8106218B2 (en) 2012-01-31
US20050282798A1 (en) 2005-12-22
CA2507710A1 (en) 2005-11-24
JP5073177B2 (ja) 2012-11-14
US20120088751A1 (en) 2012-04-12
JP2005350457A (ja) 2005-12-22
EP1602658B1 (en) 2011-12-07
CA2507710C (en) 2013-01-08
US20090081123A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
ATE536357T1 (de) Tricyclische pyrazolderivate als cannabinoidrezeptorantagonisten
ATE514690T1 (de) Pyrazolderivate mit affinität zu cb1 und/oder cb2 rezeptoren
ES2168953A1 (es) Derivados de oxima y su uso como acidos latentes
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO20054856D0 (no) 4-anilo-kinazolinderivater som antiproliferative midler
CR8264A (es) Derivados de malonamida bloqueadores de la actividad gamma-secretase
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
EA200401613A1 (ru) Лекарственное средство для лечения рака
ES2167371T3 (es) Derivados de 1h-3-aril-pirrolidin-2,4-diona espirociclicos substituidos.
WO2009095792A3 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
RS52900B (en) Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them
RS51193B (sr) Hidantoinski derivati korisni kao inhibitori metaloproteinaza
DE60011269D1 (de) Azaidole mit serotonin rezeptor affinität
MXPA05013631A (es) Derivado heterociclico de metilsulfona.
TR200102572T2 (tr) Eritromisin türevleri.
WO2007068815A3 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.
MEP26608A (en) Aminothiazole derivatives and their use as crf receptor ligands
EA200000910A1 (ru) Азабициклические лиганды рецепторов 5нт1
FI921925A0 (fi) Kemiluminescerande 3-(substituerad adamant-2-yliden)-1,2-dioxetaner.
WO2004050086A8 (fr) Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
DE69617909T2 (de) 2-substituierte vitamin-d3-derivate
HRP20030381B1 (en) 3-DECLADINOZYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICYNE A
GT200600298A (es) Derivados de n-[(4,5-difenilpirimidin-2-il)metil] amina, su preparacion y su aplicacion en terapeutica
NO20023298D0 (no) Nye imidazolderivater
DE602004028636D1 (de) Nichtmigrierendes grüngelbes metallkomplex-disazopigment